Clinical stage biopharmaceutical company focusing on gamma-delta T cells for the treatment of cancer. #CancerZero #IN8bio $INAB
Joined July 2017
- Tweets542
- Following220
- Followers575
- Likes194
Gamma-delta T cells are powerful but scarce.
INB-619 is designed to overcome that challenge with a built-in domain that both activates and expands these cells.
Preclinical studies showed consistent potency despite varying starting cell levels.
$INAB #GammaDeltaTcells #TCellEngager
CAR-T demonstrated the potential of deep B cell depletion to reset the immune system, but requires complex manufacturing and chemotherapy.
INB-619 aims for similar activity with an off-the-shelf T cell engager. No personalized cell manufacturing or lymphodepletion.
$INAB #TCellEngager #Autoimmune
Most T cell engagers activate T cells through CD3, which can trigger broad immune activation and potentially serious side effects.
INB-619 takes a different approach: selectively engaging gamma-delta T cells.
Same disease target. Different T cell.
$INAB #GammaDeltaTcells #TCellEngager
This morning, our CEO, William Ho, will participate in a Fireside Chat at the H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference.
📆 Thursday, October 15, 2026
⏰ 10:30 AM - 11:00 AM ET
🔗Click the link in the comments to register and watch live!
A live webcast and replay will be available under "Events and Presentations" in the News & Presentations section of the IN8bio website.
$INAB #CancerZero @HCWCO @willhonyc
Cancer and autoimmune disease have very different risk-benefit equations.
Most T cell engagers broadly activate the immune system, more like a sledgehammer.
INB-619 is designed to be more like a scalpel, selectively engaging gamma-delta T cells for a potentially more precise approach.
$INAB #Autoimmune #TCellEngager #Immunology
In 2021, Georg Schett at the University of Erlangen-Nuremberg published a landmark study, something the field had not seen before. He used CD19 CAR-T to deplete B cells in lupus patients. They went into drug-free remission.
The idea: wipe out the misfiring B cells and the immune system restarts from a healthier place. It has since been repeated across several autoimmune diseases.
Why CD19? Because it is the broadest target found across B cells at every stage of their life, from early precursors to mature memory cells. Other targets miss earlier stages. Dr. Schett has never seen another target after CD19.
That is the target INB-619 is built around.
#Autoimmune #CD19 #Immunology $INAB
More than 24 million Americans have an autoimmune disease.
In some of them, the cause traces to one cell type: B cells that have turned on the body.
Lupus: 200-350k
Systemic sclerosis: ~100k
Myasthenia gravis: 80-100k
Inflammatory myopathy: ~75k
Deplete those B cells and the immune system can reset. That's the thesis we're building on.
$INAB
This month we welcomed Oxana Polyakova, PhD, as SVP of Research & Development. She has spent 20 years building T cell engagers. So what exactly is one?
A T cell engager is an off-the-shelf protein with two ends. One end recognizes a T cell. The other recognizes the target. It brings them together, and the T cell does the rest to eliminate the target!
This is one way we can use the immune system without a cellular therapy.
No cells harvested from the patient. No personalized manufacturing. No lymphodepletion. Dosed like a drug.
Most engagers today work through CD3. IN8bio is building one that works through gamma-delta T cells instead. More on why in the weeks ahead.
#TCellEngager #Immunology #Biotech $INAB
Join our CEO and Co-founder, William Ho (@willhonyc), for a public group presentation at the Sidoti Small-Cap Virtual Conference this Thursday, September 24th at 1:00 p.m. ET.
In this virtual presentation, William will discuss IN8bio’s γδ T cell platforms and capabilities, including our novel T cell engager (TCE) program, INB-619 for Oncology and Autoimmune Disease.
He will also be available for one-on-one investor meetings throughout the event.
🔗 Read the full press release in the comments below to learn more and register for the webcast.
$INAB
🔗Read the press release here: investors.in8bio.com/news-re…
🔗Register for the webcast here: sidoti.zoom.us/webinar/regis…
Our President and COO, Kate Rochlin, is presenting at the 17th Annual World Bispecific Summit in Boston. She will be discussing our novel gamma-delta T Cell Engager (TCE) platform.
➡️Company presentation: "Beyond CD3: Harnessing Gamma Delta T-cells for Efficient Targeting Across Cancer & Autoimmunity."
📆 Wednesday, September 16th | 12:00 PM EDT
➡️ Panel discussion: Industry Leaders Panel Discussion "Recognizing the Different Bars for Safety & Efficacy Data for Bispecifics in Oncology versus Autoimmunity/Immunology to Identify Unrealized Market Opportunity"
📆 Thursday, September 17th | 4:30 PM EDT
